Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH2 | Q8IWU9 | 20/20 | 1.00 |
| ▸ | TPH1 | P17752 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810118 | 0.85 | TPH1 (1.00) | TPH2TPH1 | |
| SCHEMBL19827158 | 0.83 | TPH1 (1.00) | TPH2TPH1 | |
| SCHEMBL19810115 | 0.82 | TPH1 (1.00) | TPH2TPH1 | |
| SCHEMBL19827111 | 0.78 | TPH2 (1.00) | TPH2TPH1 | |
| SCHEMBL19813992 | 0.78 | TPH1 (1.00) | TPH2TPH1 | |
| SCHEMBL19817149 | 0.76 | TPH1 (1.00) | TPH2TPH1 | |
| SCHEMBL19810137 | 0.75 | TPH1 (1.00) | TPH2TPH1 | |
| SCHEMBL22105477 | 0.75 | MEN1 (0.68) | TPH2TPH1 | |
| SCHEMBL19827205 | 0.75 | TPH1 (0.85) | TPH2TPH1 | |
| SCHEMBL19810127 | 0.75 | TPH1 (1.00) | TPH2TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028104-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2021-06-08 | — | — | US | disclosed |
| US-11028104-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2021-06-08 | — | — | US | disclosed |
| EP-3490996-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2020-08-26 | — | — | EP | disclosed |
| EP-3490996-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2020-08-26 | — | — | EP | disclosed |
| US-20200262847-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2020-08-20 | — | — | US | disclosed |
| US-10683309-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2020-06-16 | — | — | US | disclosed |
| US-10683309-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2020-06-16 | — | — | US | disclosed |
| US-20190161503-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2019-05-30 | — | — | US | disclosed |
| US-20190161503-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2019-05-30 | — | — | US | disclosed |
| WO-2018019917-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-01 | — | — | WO | disclosed |
| EP-3275885-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-01-31 | — | — | EP | disclosed |
| EP-3275885-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683309-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | TPH1, XDH, TPH2 | TPH2 3/4885TPH1 1/4885 |
| US-20190161503-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | TPH2 3/4885TPH1 1/4885 |
| US-20200262847-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | TPH2 3/4885TPH1 1/4885 |
| US-11028104-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | TPH1, XDH, TPH2 | TPH2 3/4885TPH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.